| Name | NT157 |
| Description | NT157 is a small molecule tyrphostin targeting IRS protein and has the potential to inhibit IGF-1R and STAT3 signaling pathways in TME cancer cells and stromal cells, resulting in decreased cancer cell survival. |
| In vitro | NT157 treatment resulted in dose-dependent inhibition of IGF1R activation, suppression of IRS protein expression, inhibition of IGF1-induced AKT activation, but increased ERK activation in NT157-treated cells in vitro[2]. |
| In vivo | NT157 suppressed androgen-responsive growth, delayed CRPC progression of LNCaP xenografts, and suppressed PC3 tumor growth alone and in combination with docetaxel[2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 77 mg/mL (186.78 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.85 mM), Sonication is recommended. Ethanol : 25.83 mg/mL (62.65 mM), Sonication is recommended.
|
| Keywords | STAT3 | NT-157 | NT157 | NT 157 | Insulin Receptor 2 | Insulin Receptor 1 | IGF-1R | IGF1R |
| Inhibitors Related | Flubendazole | HODHBt | Nifuroxazide | Balsalazide disodium dihydrate | Ornithine-α-ketoglutarate | Niclosamide | Sorbic acid | Brigatinib | L-Cysteine hydrochloride hydrate | Tranexamic acid | Diosgenin | Niclosamide olamine |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Diabetic Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Inhibitor Library | Stem Cell Differentiation Compound Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |